Vahe Grigoryan, Assistant Managing Editor at OncoDaily Medical Journal and Host of the “OnCoffee” Podcast at OncoDaily, shared a post on LinkedIn:
“Proud and excited to share results from our poster at ESMO 2025: “Global trends in CNS tumor clinical trials: A decade of data from 950 interventional studies.”
I’m also honored to be the first person from Armenia to present a poster at the ESMO Annual Congress.
Here are some interesting and concerning results from our study:
What we analyzed:
Clinical trials registered Jan 1, 2015 – Dec 31, 2024.
Key findings:
Tumor focus: Primary brain tumors are under-represented. Many trials center on CNS metastases (43%), while GBM (9%) and glioma (11%) get fewer studies.
Geography: High-income countries ~75% of trials. UMICs ~23%, LMICs ~0.4%, and no trials in LICs. A major equity gap.
Sponsors: Academic ~70% vs industry ~19% (other 11%). In late-phase (Ph2/3–Ph3), only ~22.5% are industry-sponsored.
Endpoints: In Phase 3, overall survival (OS) is the primary endpoint in ~34% overall. Industry-led Ph3 use OS in >60%, versus ~21% for non-industry. So even with limited industry involvement, when industry is present it often drives robust, practice-focused trials.
A note from the floor.
Just a few meters from the CNS posters were metastatic breast cancer posters, and the foot traffic there was clearly heavier (see photos below). This suggests interest in CNS tumors remains limited even in academic settings, which is a serious concern. Patients with CNS tumors deserve the same attention and investment as those with any other cancer.
Grateful to all my colleagues and mentors who contributed to this work, thank you for your support and collaboration.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
